Results 1 to 10 of about 26,643,453 (321)
MMW - Fortschritte der Medizin, 2021 AbstractLipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, theLPAgene. The concentrations show a several-hundred-fold interindividual variability ranging from less than 0.1 mg/dL to more than 300 mg/dL. Lp(a) plasma concentrations above 30 mg/dL and even
openaire +4 more sources
The relationship between the level of Lр(а) and the prevalence of atherosclerosis among young patients [PDF]
Терапевтический архив, 2022 Background. Hyperlipoproteinemia (a) is an independent and cause risk factor for atherosclerotic cardiovascular diseases (ASCVD). The correlation between lipoprotein (a) Lp(a) and inflammation in the vessel wall was actively studied during the past few ...
Elena A. Klesareva +8 more
doaj +1 more source
Lipoprotein (a): Recent Updates on a Unique Lipoprotein [PDF]
Current Atherosclerosis Reports, 2021 Genetic, epidemiological, and translational data indicate that Lipoprotein (a) [Lp(a)] is likely in the causal pathway for atherosclerotic cardiovascular diseases as well as calcification of the aortic valves.Lp(a) is structurally similar to low-density lipoprotein, but in addition to apolipoprotein B-100, it has a glycoprotein apolipoprotein(a) [apo(a)
Anum Saeed +2 more
openaire +2 more sources
Lipoprotein a: An emerging risk identifier and evolving clinical target
Public Health and Toxicology, 2022 Pathophysiology, epidemiology and genetics data support the causal role of Lipoprotein a, Lp(a), in cardiovascular disease, and in aortic valve calcification and stenosis.
Konstantinos Tsarouhas* +3 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2022 Background: Patients with acute coronary syndrome (ACS) still have a high risk of recurrence of major adverse cardiovascular and cerebrovascular events (MACCE).
Cai-Yan Cui +6 more
doaj +1 more source
Journal of Clinical Lipidology, 2022 Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population.
D. Wilson +6 more
semanticscholar +1 more source
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
New England Journal of Medicine, 2022 BACKGROUND Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS We conducted a randomized, double-blind, placebo-controlled,
M. O’Donoghue +15 more
semanticscholar +1 more source
The Anti-Thrombotic Effects of PCSK9 Inhibitors
Pharmaceuticals, 2023 Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence.
Martin Jozef Péč +10 more
doaj +1 more source
Arteriosclerosis, Thrombosis and Vascular Biology, 2021 High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp(a)
G. Reyes-Soffer +9 more
semanticscholar +1 more source